Zeng's study showed that serine beta-lactamase-like protein (LACTB) was identified as a downstream target of lenvatinib, and overexpression of LACTB triggered ferroptosis through (solute carrier family 7 member 11) SLC7A11/GSH/GPX4 signalling pathway, resulting in the enhancement of lenvatinib's anti-tumor efficacy and attenuation of LR 75. This evidence concerns the gene SLC7A11 and neoplasm.